Literature DB >> 7890021

In vitro prolactin but not LH and FSH release is inhibited by compounds in extracts of Agnus castus: direct evidence for a dopaminergic principle by the dopamine receptor assay.

H Jarry1, S Leonhardt, C Gorkow, W Wuttke.   

Abstract

Women suffering from premenstrual mastodynia often respond to stimuli of prolactin (Prl) release with a hypersecretion of this hormone. Pharmacological reduction of Prl release by dopamine agonists or treatment with extracts of Agnus castus (AC) improve the clinical situation of patients with such premenstrual symptoms. Extracts of AC contain compounds which inhibit in vivo Prl release in women as well as in vitro from dispersed rat pituitary cells. It is yet unknown whether this inhibitory action of AC is only exerted on Prl release or whether release of other pituitary hormones like LH and FSH is also affected. The effects of AC on LH and FSH release were examined in vitro using rat pituitary cell cultures. To rule out that the Prl-inhibiting properties of AC are at least in part due to a cytotoxic component, pituitary cell cultures were subjected to the MTT test. To assess whether the Prl inhibitory effect of AC preparations is due to compounds acting as dopamine (DA) agonists, we used the corpus striatum membrane DA receptor binding assay. Our results demonstrate for the first time that AC extract contains an active principle that binds to the D2 receptor. Thus, it is very likely that it is this dopaminergic principle which inhibits Prl release in vitro from rat pituitary cells. Furthermore we give evidence for the specificity of action of AC on hormone release, since gonadotropin secretion remained unaffected. The findings of the present study support the therapeutical usefulness of AC extracts for treatment of premenstrual mastodynia which is associated with hypersecretion of Prl. Furthermore, the beneficial effects of AC appear to be due to the inhibition of pituitary Prl release.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7890021     DOI: 10.1055/s-0029-1211317

Source DB:  PubMed          Journal:  Exp Clin Endocrinol        ISSN: 0232-7384


  10 in total

1.  Casticin, a flavonoid isolated from Vitex rotundifolia, inhibits prolactin release in vivo and in vitro.

Authors:  Qi YE; Qiao-yan ZHANG; Cheng-jian ZHENG; Yang WANG; Lu-ping QIN
Journal:  Acta Pharmacol Sin       Date:  2010-11-01       Impact factor: 6.150

2.  Treatment for the premenstrual syndrome with agnus castus fruit extract: prospective, randomised, placebo controlled study.

Authors:  R Schellenberg
Journal:  BMJ       Date:  2001-01-20

Review 3.  Vitex negundo and its medicinal value.

Authors:  Balraj Singh Gill; Richa Mehra; Sanjeev Kumar
Journal:  Mol Biol Rep       Date:  2018-10-11       Impact factor: 2.316

Review 4.  Herbal medicine for the management of polycystic ovary syndrome (PCOS) and associated oligo/amenorrhoea and hyperandrogenism; a review of the laboratory evidence for effects with corroborative clinical findings.

Authors:  Susan Arentz; Jason Anthony Abbott; Caroline Anne Smith; Alan Bensoussan
Journal:  BMC Complement Altern Med       Date:  2014-12-18       Impact factor: 3.659

5.  Phytoconstituents from Vitex agnus-castus fruits.

Authors:  Shao-Nong Chen; J Brent Friesen; Donna Webster; Dejan Nikolic; Richard B van Breemen; Z Jim Wang; Harry H S Fong; Norman R Farnsworth; Guido F Pauli
Journal:  Fitoterapia       Date:  2010-12-13       Impact factor: 2.882

Review 6.  Vitex agnus castus: a systematic review of adverse events.

Authors:  Claudia Daniele; Joanna Thompson Coon; Max H Pittler; Edzard Ernst
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

7.  Opioidergic mechanisms underlying the actions of Vitex agnus-castus L.

Authors:  Donna E Webster; Ying He; Shao-Nong Chen; Guido F Pauli; Norman R Farnsworth; Zaijie Jim Wang
Journal:  Biochem Pharmacol       Date:  2010-09-18       Impact factor: 5.858

8.  Effect of Aslagh Capsule, a Traditional Compound Herbal Product on Oligomenorrhea in Patients with Polycystic Ovary Syndrome: A Three-Arm, Open-label, Randomized, Controlled Trial.

Authors:  Maryam Bahman; Homa Hajimehdipoor; Soodabeh Bioos; Fataneh Hashem-Dabaghian; Maryam Afrakhteh; Mojgan Tansaz
Journal:  Galen Med J       Date:  2019-06-02

9.  Nanoemulsion for improving solubility and permeability of Vitex agnus-castus extract: formulation and in vitro evaluation using PAMPA and Caco-2 approaches.

Authors:  Vieri Piazzini; Elena Monteforte; Cristina Luceri; Elisabetta Bigagli; Anna Rita Bilia; Maria Camilla Bergonzi
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

10.  Can Vitex Agnus Castus be Used for the Treatment of Mastalgia? What is the Current Evidence?

Authors:  A R Carmichael
Journal:  Evid Based Complement Alternat Med       Date:  2008-09       Impact factor: 2.629

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.